One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration

Macular DiseasesRetinal Diseases

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebneter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR, Swiss Retina Research Network

doi: 10.1007/s40123-025-01252-6

Macular Diseases

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

BMC Ophthalmol

Bantounou MA, Elsheikh M, Ijasan A, Santiago C

doi: 10.1186/s12886-025-03953-9

Macular DiseasesRetinal Diseases

Neovascular Age-Related Macular Degeneration Treated with Aflibercept: Five-Year Follow-Up and Correlation with Optical Coherence Tomography Biomarkers in a Real-World Setting

Ophthalmol Ther

Borselli M, Elfalah M, Trunfio TA, Scala A, Chisari D, Mancini A, Lucisano A, Carnovale-Scalzo G, Mollace V, Improta G, Zweifel S, Scorcia V, Toro MD, Carnevali A

doi: 10.1007/s40123-025-01232-w

Macular Diseases

Outcomes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Clin Exp Ophthalmol

Hunt A, Hashimoto Y, Young S, Arnold J, Game J, Hooper C, Field A, Barry R, Barthelmes D, Gillies M

doi: 10.1111/ceo.14589

Macular Diseases

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

J Clin Med

Hatz K, Ambresin A, Schmid M, Prünte C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM, XTEND Study Group

doi: 10.3390/jcm14072370

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Macular Diseases

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration

Acta Ophthalmol

Abu Ishkheidem I, Inci E, Breimer M, Silfverswärd ST, Zetterberg M, Grönlund MA

doi: 10.1111/aos.17590

Macular Diseases

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Ophthalmol Retina

Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D'Souza D, Guenther S, Lawrence D, Holz FG

doi: 10.1016/j.oret.2025.05.030

Macular Diseases

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration

Clin Exp Ophthalmol

Romano F, Casaluci M, Valastro A, Airaldi M, Milella P, Pozzo Giuffrida F, Cozzi E, Aretti A, Teo KY, Cheung CMG, Nassisi M, Viola F, Staurenghi G, Invernizzi A

doi: 10.1111/ceo.14608

Related content

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

Neovascular Age-Related Macular Degeneration Treated with Aflibercept: Five-Year Follow-Up and Correlation with Optical Coherence Tomography Biomarkers in a Real-World Setting

Outcomes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration